Lucentis

In the US, Lucentis (ranibizumab ophthalmic) is a member of the drug class anti-angiogenic ophthalmic agents and is used to treat Diabetic Retinopathy, Macular Degeneration and Macular Edema.

US matches:

• Lucentis


• Lucentis ophthalmic

UK matches:

• Lucentis 10 mg/ml solution for injection
• Lucentis 10 mg/ml solution for injection (SPC)

Ingredient matches for Lucentis

Ranibizumab

Ranibizumab is reported as an ingredient of Lucentis in the following countries:

• Australia


• Austria


• Belgium


• Canada


• Croatia (Hrvatska)


• Denmark


• France


• Germany


• Greece


• Hungary


• Indonesia


• Ireland


• Italy


• Netherlands


• New Zealand


• Norway


• Peru


• Slovenia


• Spain


• Sweden


• Switzerland


• United Kingdom


• United States

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.